Intrepid Family Office LLC Has $929,000 Stock Holdings in Natera, Inc. $NTRA

Intrepid Family Office LLC decreased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 35.3% in the second quarter, Holdings Channel reports. The firm owned 5,500 shares of the medical research company’s stock after selling 3,000 shares during the quarter. Natera comprises about 0.8% of Intrepid Family Office LLC’s portfolio, making the stock its 25th biggest holding. Intrepid Family Office LLC’s holdings in Natera were worth $929,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Guided Capital Wealth Management LLC raised its holdings in shares of Natera by 0.5% in the 2nd quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock worth $2,219,000 after buying an additional 66 shares in the last quarter. Main Management ETF Advisors LLC grew its position in Natera by 1.7% in the second quarter. Main Management ETF Advisors LLC now owns 4,398 shares of the medical research company’s stock valued at $743,000 after acquiring an additional 72 shares during the period. Wedmont Private Capital raised its stake in Natera by 4.9% during the second quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company’s stock worth $256,000 after acquiring an additional 74 shares in the last quarter. Compound Planning Inc. lifted its holdings in shares of Natera by 4.2% during the first quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company’s stock valued at $271,000 after acquiring an additional 78 shares during the period. Finally, Integrated Wealth Concepts LLC boosted its stake in shares of Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Insider Transactions at Natera

In other Natera news, CFO Michael Burkes Brophy sold 1,867 shares of the business’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $190.64, for a total transaction of $355,924.88. Following the completion of the sale, the chief financial officer directly owned 64,126 shares of the company’s stock, valued at approximately $12,224,980.64. The trade was a 2.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Roelof Botha sold 75,000 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $236.12, for a total transaction of $17,709,000.00. Following the transaction, the director owned 1,154,198 shares in the company, valued at approximately $272,529,231.76. The trade was a 6.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 307,687 shares of company stock valued at $63,466,360. 5.63% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on NTRA shares. JPMorgan Chase & Co. increased their target price on shares of Natera from $240.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 25th. BNP Paribas raised shares of Natera to a “hold” rating and set a $172.00 price objective on the stock in a research note on Monday, October 27th. Evercore ISI raised their price objective on shares of Natera from $190.00 to $250.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Zacks Research downgraded Natera from a “hold” rating to a “strong sell” rating in a report on Monday, October 20th. Finally, Stephens raised their price target on Natera from $197.00 to $235.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Fifteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $225.29.

Natera Price Performance

NTRA stock opened at $239.14 on Tuesday. The company has a 50 day moving average price of $201.07 and a 200 day moving average price of $174.58. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $246.90. The stock has a market capitalization of $33.00 billion, a PE ratio of -104.43 and a beta of 1.63.

Natera (NASDAQ:NTRA) last released its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The firm’s quarterly revenue was up 34.7% on a year-over-year basis. During the same period last year, the business posted ($0.26) earnings per share. As a group, equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.